Zimmer Confirms Ongoing FDA Attention To Warsaw Plant

Zimmer Biomet saw increased growth during the second quarter – but the company also confirmed on its recent Q2 earnings call that its quality remediation efforts continue, with fresh FDA observations arising from the agency's most recent inspection of one of Zimmer's Indiana-based manufacturing facilities.

Enlarged eye of tax inspector looking through magnifying glass, inspecting offshore company financial papers, documents and reports.
• Source: Shutterstock

ZimmerBiomet Holdings Inc. confirmed on a recent earnings call that the company’s US FDA quality systems compliance challenges aren’t over quite yet.

The firm received additional observations after FDA’s most recent inspection of its Warsaw North Campus facility in Warsaw, Ind., President...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Compliance

More from Policy & Regulation